Skip to Main Content
Table 1

Baseline characteristics of CANVAS participants with samples available for IGFBP7 analysis

CharacteristicCanagliflozin (n = 2,384)Placebo (n = 1,193)
Age, years 62.8 (7.9) 62.5 (7.8) 
Female, n (%) 789 (33) 395 (33) 
Race, n (%)   
 White 1,941 (81) 968 (81) 
 Asian 233 (10) 121 (10) 
 Black 55 (2) 31 (3) 
eGFR, mL/min/1.73 m2 77.2 (18.7) 76.8 (19.0) 
BMI, kg/m2 32.7 (6.1) 32.6 (6.2) 
SBP, mmHg 136.4 (15.9) 137.2 (15.8) 
HbA1c, % 8.2 (0.9) 8.2 (0.9) 
HbA1c, mmol/mol 66 (9.8) 66 (9.8) 
Diabetes duration, years 13.6 (7.5) 13.4 (7.5) 
UACR, mg/g 9.1 (35.7) 11.3 (40.4) 
History of heart failure, n (%) 296 (12) 170 (13) 
Diuretic use, n (%) 1,109 (47) 552 (46) 
Sulfonylurea use, n (%) 1,043 (44) 521 (44) 
GLP-1 use, n (%) 60 (3) 26 (2) 
Statin use, n (%) 1,787 (75) 866 (73) 
Insulin use, n (%) 1,258 (53) 621 (52) 
Metformin use, n (%) 1,737 (73) 858 (72) 
RAAS inhibitor use, n (%) 1,950 (82) 977 (82) 
β-Blocker use, n (%) 1,210 (51) 605 (51) 
CharacteristicCanagliflozin (n = 2,384)Placebo (n = 1,193)
Age, years 62.8 (7.9) 62.5 (7.8) 
Female, n (%) 789 (33) 395 (33) 
Race, n (%)   
 White 1,941 (81) 968 (81) 
 Asian 233 (10) 121 (10) 
 Black 55 (2) 31 (3) 
eGFR, mL/min/1.73 m2 77.2 (18.7) 76.8 (19.0) 
BMI, kg/m2 32.7 (6.1) 32.6 (6.2) 
SBP, mmHg 136.4 (15.9) 137.2 (15.8) 
HbA1c, % 8.2 (0.9) 8.2 (0.9) 
HbA1c, mmol/mol 66 (9.8) 66 (9.8) 
Diabetes duration, years 13.6 (7.5) 13.4 (7.5) 
UACR, mg/g 9.1 (35.7) 11.3 (40.4) 
History of heart failure, n (%) 296 (12) 170 (13) 
Diuretic use, n (%) 1,109 (47) 552 (46) 
Sulfonylurea use, n (%) 1,043 (44) 521 (44) 
GLP-1 use, n (%) 60 (3) 26 (2) 
Statin use, n (%) 1,787 (75) 866 (73) 
Insulin use, n (%) 1,258 (53) 621 (52) 
Metformin use, n (%) 1,737 (73) 858 (72) 
RAAS inhibitor use, n (%) 1,950 (82) 977 (82) 
β-Blocker use, n (%) 1,210 (51) 605 (51) 

Data are mean (SD) unless otherwise indicated. GLP-1, glucagon-like peptide 1; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure.

Close Modal

or Create an Account

Close Modal
Close Modal